

Special Issue

Gene Editing for Therapy and Reverse Genetics of Blood Diseases

Message from the Guest Editor

Gene editing is increasingly taking center stage for both basic research and translational studies. The key driver of this development is the rapidly growing adoption of editing technology and, in particular, fast-evolving RNA-guided CRISPR/Cas tools, which, with their versatility and ease of use, have facilitated the development of double-strand-break-independent editors and the exploration of new fields of application. In particular blood biology and disorders are a favorite focus of gene editing, motivated by a relatively high prevalence of monogenic, infectious and complex diseases affecting blood cells, and helped by the accessibility of hematopoietic stem and progenitor cells for manipulation.

This Special Issue aims to showcase the application of gene editing technology in therapy development and research for blood diseases. We welcome Articles, Communications and Reviews providing new insights into (i) developmental and disease mechanisms; (ii) the establishment or study of disease models; (iii) the creation of new editing platforms and molecules for diagnosis, functional study or therapy; (vi) the refinement of corresponding delivery, targeting and culture procedures.

Guest Editor

Dr. Carsten W. Lederer

Molecular Genetics Thalassemia Department, The Cyprus Institute of Neurology & Genetics, Nicosia 2371, Cyprus

Deadline for manuscript submissions

closed (20 March 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/82236

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham,
1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))